Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing
This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.
📰 Original Source
Read full article at Fool →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.